TY - JOUR
T1 - Neuropsychopharmacology
T2 - Are we ready for a paradigm shift?
AU - Meyer, Roger E.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1996/3
Y1 - 1996/3
N2 - The 'paradigm shift' in the title of this article refers to molecular biology. The real challenge to molecular biologists interested in applying their methods to an understanding of psychiatric disorders involves the development of models that account for gene/environment/development interaction. Because of the existence of homologous animal models of additive disorders, as well as a rich body of clinical observations and clinical and behavioral research, and recent data suggesting that chronic exposure to addictive drugs results in changes in gene expression in neurons from behaviorally relevant brain regions, additive disorders offer a serendipitous model (to molecular biologists) that may have relevance to subsequent application in other areas of psychiatry and psychology.
AB - The 'paradigm shift' in the title of this article refers to molecular biology. The real challenge to molecular biologists interested in applying their methods to an understanding of psychiatric disorders involves the development of models that account for gene/environment/development interaction. Because of the existence of homologous animal models of additive disorders, as well as a rich body of clinical observations and clinical and behavioral research, and recent data suggesting that chronic exposure to addictive drugs results in changes in gene expression in neurons from behaviorally relevant brain regions, additive disorders offer a serendipitous model (to molecular biologists) that may have relevance to subsequent application in other areas of psychiatry and psychology.
UR - http://www.scopus.com/inward/record.url?scp=0030000511&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030000511&partnerID=8YFLogxK
U2 - 10.1016/0893-133X(95)00074-N
DO - 10.1016/0893-133X(95)00074-N
M3 - Article
C2 - 8866700
AN - SCOPUS:0030000511
VL - 14
SP - 169
EP - 179
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
SN - 0893-133X
IS - 3
ER -